Ref. No.P-66/2026-27/52
November 13, 2026

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Subject: Outcome of Board Meeting held on Friday, 13th November, 2026

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that, the Board of Directors of the Company at its Meeting held today i.e. 13th November, 2026, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on 30th September 2026 along with Statement of Assets and Liabilities as at 30th September 2026 (Standalone and Consolidated) and Statement of Cash Flow for the half year ended on 30th September 2026 (Standalone and Consolidated). The same has also been reviewed by the Audit Committee in its meeting held earlier today.

Further, M/s Baheti & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2026 and the Board has also taken on record their Limited Review Reports on the said Financial Results. A copy of the Limited Review Reports along with the Financial Results is enclosed herewith.

The meeting of the Board of Directors commenced at 3:00 p.m. and concluded at 3:45 p.m.

You are requested to take the same on record.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

NIKHILKUBER DUBEY
Digitally signed by NIKHILKUBER DUBEY
Date: 2026.11.13 15:50:55 +05'30'

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: As above

M/s 3B BLACKBIO DX LTD

(Formerly M/s KILPEST INDIA LTD)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023

CIN:L24211MP1972PLC001131

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30-09-2026

(Rs in lakhs)

S.No.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
I	Revenue from operations	3650.65	2294.52	2791.16	5945.17	4826.87	9727.50
II	Other income	246.20	530.27	391.31	776.47	822.73	1416.20
III	**Total Income (I + II)**	**3896.85**	**2824.79**	**3182.47**	**6721.64**	**5649.60**	**11143.70**
IV	**Expenses:**						
	Cost of materials consumed	813.01	493.25	683.11	1306.26	1202.81	2345.16
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	19.22	(29.94)	6.42	(10.72)	0.45	11.69
	Employee benefits expenses	247.05	182.86	215.63	429.91	364.44	757.93
	Finance costs	0.04	0.02	1.20	0.06	2.00	4.39
	Depreciation and amortization expense	23.50	23.50	21.50	47.00	43.00	94.31
	Other expenses	370.53	319.78	302.27	690.31	516.62	1294.54
	Total expenses (IV)	**1473.35**	**989.47**	**1230.13**	**2462.82**	**2129.32**	**4508.02**
V	**Profit/(loss) before exceptional items and tax (III - IV)**	**2423.50**	**1835.32**	**1952.34**	4258.82	**3520.28**	**6635.68**
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	**Profit before tax (V - VI)**	**2423.50**	**1835.32**	**1952.34**	**4258.82**	**3520.28**	**6635.68**
VIII	Tax expense:						
	(1) Current tax	627.36	424.11	458.26	1051.47	780.16	1615.49
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	88.50
IX	Profit (Loss) for the period (VII-VIII)	**1796.14**	**1411.21**	**1494.08**	**3207.35**	**2740.12**	**4931.69**
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	**1796.14**	**1411.21**	**1494.08**	**3207.35**	**2740.12**	**4931.69**
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	31044.75	31044.75	26421.76	31044.75	26421.76	26421.76
XIV	**Earnings per equity share:**						
	(1) Basic	20.96	16.47	17.44	37.43	31.98	57.56
	(2) Diluted	20.96	16.47	17.44	37.43	31.98	57.56

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Ltd. BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL

DATE: 13/11/2026

M/s 3B BLACKBIO DX LTD

(Formerly M/s KILPEST INDIA LTD)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023

CIN:L24211MP1972PLC001131

Standalone UnAudited Balance Sheet As On 30-09-2026 (Rs. in Lakhs)

PARTICULARS	STANDALONE	
ASSETS	As at 30-09-2026 Un-Audited	As at 31-03-2026 Audited
Non-current assets		
(a) Property, Plant and Equipment	647.09	680.34
(b) Capital work-in-progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financial Assets	0.00	0.00
(i) Investments	19899.67	18809.84
(ii) Trade receivables	0.00	0.00
(iii) Loans	311.57	311.57
(i) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	0.00	**0.00**
Current assets		
(a) Inventories	554.15	656.53
(b) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Trade receivables	5687.71	4319.72
(iii) Cash and cash equivalents	1392.41	1679.52
(iv) Bank balances other than(iii) above	7288.11	6230.52
(v) Other Financial Assets	19.20	20.42
(vi) Loans	0.00	0.00
(vii) Others (to be specified)	0.00	0.00
(c) Current Tax Assets (Net)	0.00	0.00
(d) Other current assets	1575.70	2329.00
Total Assets	**37375.61**	**35037.46**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	856.84	856.84
(b) Other Equity		
Equity Attributable to Owners of the Co.	33841.07	31044.75
Non-Controlling Interest	0.00	0.00
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	0.00	0.00
(ii) Trade payables	0.00	0.00
(iii)Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deferred tax liabilities (Net)	670.34	670.34
(d) Other non-current liabilities	0.00	0.00
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade payables		
Total outstanding dues of Micro Enterprises and Small Enterprises	37.78	0.00
Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	71.26	134.04
(iii) Other financial liabilities (other than those specified in item (c)	56.70	56.70
(b) Other current liabilities	790.15	674.79
(c) Provisions	1051.47	1600.00
(d) Current Tax Liabilities (Net)	0.00	0.00
Total Equity and Liabilities	**37375.61**	**35037.46**

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Ltd. BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13/11/2026

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023
CIN:L24211MP1972PLC001131

STANDALONE UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026

(Rs. in Lakhs)

	PARTICULARS	For the half year ended 30th Sept 2026	For the year ended 31st March 2026
		Un-Audited	Audited
A	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit Before Tax & Extra-Ordinary Items	4258.82	6635.68
	Adjustments for:		
	Depreciation	47.00	94.31
	Interest Paid	0.06	4.39
	Unrealised Gain on Investments carried at Fair Value through P&L	(353.31)	(297.40)
	Operating Profit before working capital changes	**3952.57**	**6436.98**
	Adjustments for:		
	Inventories	102.38	157.35
	Trade and other Receivables	(613.47)	(1341.39)
	Trade Payables and Other Liabilities	(458.17)	644.62
	Cash generated from operations	2983.31	5897.56
	Income tax payments	(1051.47)	(1615.49)
	Net Cash used/ available from Operating Activities (A)	**1931.84**	**4282.07**
B	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Purchase / Sale of Fixed Assets	(13.75)	(137.59)
	Acquisition of Investment (Net of Sales)	(736.52)	(1842.44)
	Decrease in other non current assets	0.00	0.00
	Net Cash Used in Investing Activities (B)	**(750.27)**	**(1980.03)**
C	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Increase in non current assets	0.00	(311.57)
	Capital Subsidy Received	16.77	33.55
	Increase/Decrease in bank borrowings	0.00	0.00
	Decrease in Other Non Current Liability	0.00	(30.69)
	Increase/Decrease in other borrowings	0.00	0.00
	Interest Paid	(0.06)	(4.39)
	Equity Dividend Paid	(427.80)	(342.25)
	Net Cash From Financing activities (C)	**(411.09)**	**(655.35)**
	Net Increase /Decrease in Cash & Cash equivalents (A+B+C)	**770.48**	**1646.69**
	Cash & Cash equivalents as at 1st April opening balance	7910.04	6263.35
	Cash & Cash equivalents as at 30th Sept closing balance	**8680.52**	**7910.04**

FOR AND ON BEHALF OF THE BOARD

3B BlackBio DX Limited BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13/11/2026

BAHETI & CO.
CHARTERED ACCOUNTANTS
24,M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (the "Company") for the quarter ended September 30, 2026 and year to date from April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants

BAHETI & CO. Reg. No. 006287C BHOPAL CHARTERED ACCOUNTANTS

(DEEPAK BAHETI)
Partner
Membership No.075063
UDIN 26075063RHMZUG4778

Place: Bhopal
Date: 13/11/2026

NOTES ON STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30th SEPTEMBER, 2026

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on November 13, 2026 after being reviewed by the Audit Committee.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared In accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. All the figures of financials have been rounded off to nearest lakh in rupees.
5. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
6. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)
7. The results of the company are available for investors at www.kilpest.com and www.bseindia.com.

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter and half year ended September 30, 2026 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

* NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

PLACE: BHOPAL
DATE: 13/11/2026

M/s 3B BLACKBIO DX LTD

(Formerly M/s KILPEST INDIA LTD)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023

CIN:L24211MP1972PLC001131

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30-09-2026

(Rs in lakhs)

S.No	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
I	Revenue from operations	4828.02	3349.08	3390.21	8177.10	5613.67	14191.81
II	Other income	470.76	614.30	550.59	1085.06	982.25	2555.81
III	**Total Income (I + II)**	**5298.78**	**3963.38**	**3940.80**	**9262.16**	**6595.92**	**16747.62**
IV	**Expenses:**						
	Cost of materials consumed	1106.70	785.08	918.76	1891.78	1480.68	3573.85
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	19.22	(29.94)	6.42	(10.72)	0.45	11.68
	Employee benefits expenses	783.37	854.74	462.79	1638.11	639.33	2396.48
	Finance costs	5.95	10.25	3.53	16.20	4.58	23.71
	Depreciation and amortization expense	140.83	134.39	58.20	275.22	85.87	512.56
	Other expenses	813.02	886.91	529.08	1699.93	836.64	2532.37
	Total expenses (IV)	**2869.09**	**2641.43**	**1978.78**	**5510.52**	**3047.55**	**9050.65**
V	**Profit/(loss) before exceptional items and tax (III - IV)**	**2429.69**	**1321.95**	**1962.02**	**3751.64**	**3548.37**	**7696.97**
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	**Profit before tax (V - VI)**	**2429.69**	**1321.95**	**1962.02**	**3751.64**	**3548.37**	**7696.97**
VIII	Tax expense:						
	(1) Current tax	627.36	424.11	458.26	1051.47	780.16	1615.49
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	88.50
IX	Profit (Loss) for the period (VII-VIII)	**1802.33**	**897.84**	**1503.76**	**2700.17**	**2768.21**	**5992.98**
	Profit or loss, attributable to owners of parent	**1779.58**	**953.19**	**1471.19**	**2732.77**	**2730.12**	**5858.59**
	Total profit or loss, attributable to non-controlling interests	**22.75**	**(55.35)**	**32.57**	**(32.60)**	**38.09**	**134.39**
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	**1802.33**	**897.84**	**1503.76**	**2700.17**	**2768.21**	**5992.98**
	Profit or loss, attributable to owners of parent	**1779.58**	**953.19**	**1471.19**	**2732.77**	**2730.12**	**5858.59**
	Total profit or loss, attributable to non-controlling interests	**22.75**	**(55.35)**	**32.57**	**(32.60)**	**38.09**	**134.39**
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	32307.03	32307.03	26243.65	32307.03	26243.65	26243.65
XIV	**Earnings per equity share:**						
	(1) Basic	21.03	10.48	17.55	31.51	32.31	69.94
	(2) Diluted	21.03	10.48	17.55	31.51	32.31	69.94

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13/11/2026

M/s 3B BLACKBIO DX LTD

(Formerly M/s KILPEST INDIA LTD)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHÓPAL–462 023

CIN:L24211MP1972PLC001131

Consolidated UnAudited Balance Sheet as on 30-09-2026 (Rs. in Lakhs)

PARTICULARS	CONSOLIDTAED	
ASSETS	**As at 30-09-2026 Un-Audited**	**As at 31-03-2026 Audited**
Non-current assets		
(a) Property, Plant and Equipment	2561.35	2760.27
(b) Capital work-in-progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financial Assets	0.00	0.00
(i) Investments	16864.14	15770.45
(ii) Trade receivables	0.00	0.00
(iii) Loans	0.00	0.00
(i) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	2.55	2.55
Current assets		
(a) Inventories	1799.36	1837.77
(b) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Trade receivables	6424.51	5008.91
(iii) Cash and cash equivalents	3399.02	3831.39
(iv) Bank balances other than(iii) above	7288.11	6230.52
(v) Other Financial Assets	19.20	20.42
(vi) Loans	0.00	0.00
(vii) Others (to be specified)	0.00	0.00
(c) Current Tax Assets (Net)	0.00	0.00
(d) Other current assets	1863.35	2337.25
Total Assets	**40221.59**	**37799.53**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	856.84	856.84
(b) Other Equity		
Equity Attributable to Owners of the Co.	33900.41	31581.35
Non-Controlling Interest	696.16	725.68
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	310.46	310.66
(ii) Trade payables	0.00	0.00
(iii)Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deferred tax liabilities (Net)	670.34	670.34
(d) Other non-current liabilities	0.00	0.00
Current liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	0.00	0.00
(ii) Trade payables		
Total outstanding dues of Micro Enterprises and Small Enterprises	37.78	0.00
Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	213.33	692.41
(iii) Other financial liabilities (other than those specified in item (c)	56.70	56.70
(b) Other current liabilities	2428.10	1305.55
(c) Provisions	1051.47	1600.00
(d) Current Tax Liabilities (Net)	0.00	0.00
Total Equity and Liabilities	**40221.59**	**37799.53**

FOR AND ON BEHALF OF THE BOARD

PLACE : BHOPAL
DATE: 13/11/2026

NIKHILKUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

M/s 3B BLACKBIO DX LTD

(Formerly M/s KILPEST INDIA LTD)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023

CIN:L24211MP1972PLC001131

CONSOLIDATED UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026

(Rs in lakhs)

	PARTICULARS	For the half year ended 30th Sept 2026	For the year ended 31st March 2026
		Un-Audited	Audited
A	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit Before Tax & Extra-Ordinary Items	3751.64	7696.97
	Adjustments for:		
	Depreciation	275.22	512.56
	Interest Paid	16.20	23.71
	Unrealised Gain on Investments carried at Fair Value through P&L	(353.31)	(297.40)
	Operating Profit before working capital changes	**3689.75**	**7935.84**
	Adjustments for:		
	Inventories	38.41	(963.57)
	Trade and other Receivables	(940.48)	(1868.29)
	Trade Payables and Other Liabilities	132.72	1759.10
	Cash generated from operations	2920.40	6863.08
	Income tax payments	(1051.47)	(1615.49)
	Net Cash used/ available from Operating Activities (A)	**1868.93**	**5247.59**
B	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Purchase / Sale of Fixed Assets	(76.30)	(2550.97)
	Acquisition of Subsidiary (Net of Investment)	0.00	765.79
	Acquisition of Investment (Net of Sales)	(740.38)	(571.53)
	Decrease in other non current assets	0.00	(2.55)
	Net Cash Used in Investing Activities (B)	**(816.68)**	**(2359.26)**
C	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Increase in share capital	0.00	0.00
	Capital Subsidy Received	16.77	33.55
	Increase/Decrease in bank borrowings	0.00	0.00
	Decrease in other borrowings	(0.20)	279.97
	Decrease/Increase in Other Non Current Liability	0.00	0.00
	Interest Paid	(16.20)	(23.71)
	Equity Dividend Paid	(427.80)	(342.25)
	Net Cash From Financing activities (C)	**(427.43)**	**(52.44)**
	Net Increase /Decrease in Cash & Cash equivalents (A+B+C)	**624.82**	**2835.89**
	Cash & Cash equivalents as at 1st April opening balance	10061.91	6883.22
	Exchange difference on translation of foreign currency cash & cash equivalents	0.40	342.80
	Cash & Cash equivalents as at 30th Sept closing balance	**10687.13**	**10061.91**

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13/11/2026

BAHETI & CO.
CHARTERED ACCOUNTANTS
24,M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)('hereinafter referred to as 'the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2026 and year to date from April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BAHETI & CO. Reg. No. 006287C BHOPAL CHARTERED ACCOUNTANTS

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

i. 3B BlackBio Dx Limited (Formerly, Kilpest India Limited, Holding)
ii. TRUPCR Europe Limited (Subsidiary)
iii. Coris Holding SRL, Belgium (Subsidiary)

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of these subsidiaries has not been reviewed by their auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, are based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants

BAHETI & CO. ★ Reg. No. 006287C BHOPAL ★ CHARTERED ACCOUNTANTS

Place: Bhopal
Date: 13/11/2026

(DEEPAK BAHETI)
Partner
Membership No.075063

UDIN 26075063QGSBFK6619

NOTES ON CONSOLIDATED UN-AUDITED FINANCIAL RESULT FOR THE QUARTER AND HALF-YEAR ENDED 30th SEPTEMBER, 2026

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on November 13, 2026 after being reviewed by the Audit Committee.

2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;

3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)

4. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30-09 2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
Total Income (Rs Lakhs)	3896.85	2824.79	3182.47	6721.64	5649.60	11143.70
Profit Before Tax (Rs Lakhs)	2423.50	1835.32	1952.34	4258.82	3520.28	6635.68
Profit After Tax (Rs Lakhs)	1796.14	1411.21	1494.08	3207.35	2740.12	4931.69
Basic Earnings Per Share (Rs)	20.96	16.47	17.44	37.43	31.98	57.56

5. The Consolidated Financials include the Financials of Subsidiary Companies also.

6. All the figures of financials have been rounded off to nearest lakh in rupees.

7. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.

3B BlackBio Dx Limited BHOPAL

8. The Results of the Company are available for investors at www.kilpest.com and www.bseindia.com

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended September 30, 2026 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

PLACE: BHOPAL
DATE: 13/11/2026

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023
CIN:L24211MP1972PLC001131

CONSOLIDATED SEGMENTWISE REVENUE AND RESULTS

(Rs. in Lakhs)

		Quarter ended 30-09-2026 Unaudited	Quarter ended 30-06-2026 Unaudited	Quarter ended 30-09-2025 Unaudited	Half Year ended 30-09-2026 Unaudited	Half Year ended 30-09-2025 Unaudited	Year ended 31-03-2026 Audited
1	**Segment Revenue**						
	(a)Agrochemicals	325.54	143.34	347.38	468.88	574.78	1080.00
	(b) Diagnostic kits	4502.48	3205.74	3042.83	7708.22	5038.89	13111.81
	Total income from operations (net)	**4828.02**	**3349.08**	**3390.21**	**8177.10**	**5613.67**	**14191.81**
2	**Segment Results**						
	(a)Agrochemicals	(6.82)	0.03	27.22	(6.78)	22.86	14.12
	(b) Diagnostic kits	2442.46	1332.16	1938.32	3774.62	3530.09	7706.56
	Total Segment Profit before Interest and Tax	**2435.64**	**1332.19**	**1965.55**	**3767.84**	**3552.95**	**7720.68**
	Less : Interest Expense						
	(a)Agrochemicals	0.04	0.02	1.21	0.06	2.00	4.39
	(b) Diagnostic kits	5.91	10.22	2.32	16.14	2.58	19.32
	Profit before Tax	**2429.69**	**1321.95**	**1962.02**	**3751.64**	**3548.37**	**7696.97**
3	**Segment Assets**						
	(a)Agrochemicals	2796.37	2786.22	2790.51	2796.37	2790.51	2717.78
	(b) Diagnostic kits	37425.22	35912.99	31292.49	37425.22	31292.49	35081.75
	Total Segment Assets	**40221.59**	**38699.21**	**34083.00**	**40221.59**	**34083.00**	**37799.53**
4	**Segment Liabilities**						
	(a)Agrochemicals	270.39	253.39	243.51	270.39	243.51	201.73
	(b) Diagnostic kits	4497.80	5281.95	3443.30	4497.80	3443.30	4433.93
	Total Segment Liabilities	**4768.18**	**5535.34**	**3686.81**	**4768.18**	**3686.81**	**4635.66**
	(a)Agrochemicals	2525.98	2532.83	2547.00	2525.98	2547.00	2516.05
	(b) Diagnostic kits	32927.43	30631.04	27849.19	32927.43	27849.19	30647.82
5	**Capital Employed**	**35453.41**	**33163.87**	**30396.19**	**35453.41**	**30396.19**	**33163.87**

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13/11/2026